[go: up one dir, main page]

GR3036382T3 - Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates - Google Patents

Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates

Info

Publication number
GR3036382T3
GR3036382T3 GR20010401238T GR20010401238T GR3036382T3 GR 3036382 T3 GR3036382 T3 GR 3036382T3 GR 20010401238 T GR20010401238 T GR 20010401238T GR 20010401238 T GR20010401238 T GR 20010401238T GR 3036382 T3 GR3036382 T3 GR 3036382T3
Authority
GR
Greece
Prior art keywords
piperidino
solvates
salts
pharmaceutical composition
oral administration
Prior art date
Application number
GR20010401238T
Other languages
English (en)
Inventor
Bernard Abramovici
Christian Condamine
Jean-Claude Gromenil
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of GR3036382T3 publication Critical patent/GR3036382T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR20010401238T 1997-03-28 2001-08-10 Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates GR3036382T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9703835A FR2761266B1 (fr) 1997-03-28 1997-03-28 Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
PCT/FR1998/000631 WO1998043636A1 (fr) 1997-03-28 1998-03-27 Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates

Publications (1)

Publication Number Publication Date
GR3036382T3 true GR3036382T3 (en) 2001-11-30

Family

ID=9505295

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010401238T GR3036382T3 (en) 1997-03-28 2001-08-10 Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates

Country Status (40)

Country Link
US (1) US6893659B2 (el)
EP (1) EP0969832B1 (el)
JP (1) JP3805797B2 (el)
KR (1) KR100479521B1 (el)
CN (1) CN1126543C (el)
AR (1) AR012160A1 (el)
AT (1) ATE202703T1 (el)
AU (1) AU740486B2 (el)
BR (1) BR9808429A (el)
CA (1) CA2284051C (el)
CO (1) CO4950527A1 (el)
CY (2) CY2275B1 (el)
CZ (1) CZ292129B6 (el)
DE (1) DE69801045T2 (el)
DK (1) DK0969832T3 (el)
DZ (1) DZ2453A1 (el)
EE (1) EE04578B1 (el)
ES (1) ES2161049T3 (el)
FR (1) FR2761266B1 (el)
GR (1) GR3036382T3 (el)
HR (1) HRP980163B1 (el)
HU (1) HU224838B1 (el)
ID (1) ID22973A (el)
IL (1) IL131818A (el)
IS (1) IS1960B (el)
MY (1) MY121733A (el)
NO (1) NO321615B1 (el)
NZ (1) NZ337736A (el)
PL (1) PL191107B1 (el)
PT (1) PT969832E (el)
RS (1) RS49606B (el)
RU (1) RU2193886C2 (el)
SA (1) SA98190095B1 (el)
SI (1) SI0969832T1 (el)
SK (1) SK283265B6 (el)
TR (1) TR199902236T2 (el)
TW (1) TW565450B (el)
UA (1) UA49056C2 (el)
WO (1) WO1998043636A1 (el)
ZA (1) ZA982609B (el)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
MXPA05004115A (es) * 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
AU2005278781B2 (en) 2004-07-12 2009-06-18 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2584806C (en) 2004-11-01 2014-06-17 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
JP2008523684A (ja) * 2004-12-07 2008-07-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ インテリジェントポースボタン
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1745783A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
EA015107B1 (ru) * 2006-05-31 2011-06-30 Солвей Фармасьютикалс Б.В. Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
US7786144B2 (en) 2006-05-31 2010-08-31 Solvay Pharmaceuticals B.V. Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2913018A1 (fr) * 2007-02-23 2008-08-29 Sanofi Aventis Sa Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
FR2919868A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n,n-dimethyformamide de rimonabant, et son procede de preparation
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5635991B2 (ja) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1395724B1 (it) 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
IT1396951B1 (it) 2009-12-18 2012-12-20 Neuroscienze Pharmaness S C A R L Composti farmaceutici
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10554908B2 (en) * 2016-12-05 2020-02-04 Facebook, Inc. Media effect application
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
AU2018277520B2 (en) 2017-05-31 2022-03-17 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4200295A1 (en) 2020-08-18 2023-06-28 Merck Sharp & Dohme LLC Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR656354A (fr) * 1927-11-07 1929-05-07 British Maxium Ltd Procédé de purification des métaux
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US5087454A (en) * 1990-07-30 1992-02-11 American Home Products Corporation Ibuprofen tablet
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability

Also Published As

Publication number Publication date
IS1960B (is) 2004-11-15
HRP980163A2 (en) 1998-12-31
DE69801045D1 (de) 2001-08-09
CZ344199A3 (cs) 2000-01-12
NZ337736A (en) 2001-02-23
EP0969832A1 (fr) 2000-01-12
IL131818A0 (en) 2001-03-19
HUP0001894A3 (en) 2002-01-28
NO994706L (no) 1999-11-25
DE69801045T2 (de) 2002-03-14
AU7052798A (en) 1998-10-22
ATE202703T1 (de) 2001-07-15
JP2001517224A (ja) 2001-10-02
CN1126543C (zh) 2003-11-05
DZ2453A1 (fr) 2004-07-14
ZA982609B (en) 1998-09-30
YU47099A (sh) 2002-06-19
HRP980163B1 (en) 2002-10-31
EP0969832B1 (fr) 2001-07-04
WO1998043636A1 (fr) 1998-10-08
CZ292129B6 (cs) 2003-08-13
RS49606B (sr) 2007-06-04
AR012160A1 (es) 2000-09-27
EE9900441A (et) 2000-04-17
TW565450B (en) 2003-12-11
CA2284051A1 (en) 1998-10-08
CA2284051C (en) 2005-01-11
SK283265B6 (sk) 2003-04-01
ES2161049T3 (es) 2001-11-16
RU2193886C2 (ru) 2002-12-10
CY2275B1 (en) 2003-07-04
US6893659B2 (en) 2005-05-17
HU224838B1 (en) 2006-03-28
TR199902236T2 (xx) 1999-12-21
IL131818A (en) 2003-07-31
SA98190095B1 (ar) 2006-06-18
FR2761266A1 (fr) 1998-10-02
JP3805797B2 (ja) 2006-08-09
CY2006005I1 (el) 2009-11-04
PL191107B1 (pl) 2006-03-31
NO994706D0 (no) 1999-09-27
CY2006005I2 (el) 2009-11-04
FR2761266B1 (fr) 1999-07-02
KR100479521B1 (ko) 2005-03-30
US20030003145A1 (en) 2003-01-02
BR9808429A (pt) 2000-05-23
MY121733A (en) 2006-02-28
UA49056C2 (uk) 2002-09-16
SK130999A3 (en) 2000-03-13
AU740486B2 (en) 2001-11-08
ID22973A (id) 1999-12-23
SI0969832T1 (el) 2001-12-31
DK0969832T3 (da) 2001-10-22
PT969832E (pt) 2001-11-30
KR20010005752A (ko) 2001-01-15
HK1022831A1 (en) 2000-08-25
PL335942A1 (en) 2000-05-22
CN1251524A (zh) 2000-04-26
IS5190A (is) 1999-09-23
HUP0001894A2 (hu) 2001-04-28
EE04578B1 (et) 2006-02-15
NO321615B1 (no) 2006-06-12
CO4950527A1 (es) 2000-09-01

Similar Documents

Publication Publication Date Title
HUP0001894A3 (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
HUP0004050A3 (en) Itraconazole exhibiting improved solubility, a method of preparing the same and pharmaceutical composition for oral administration comprising the same
EP0873749A4 (en) GELLED PRODUCTS FOR ORAL ADMINISTRATION
HUP9603064A2 (en) New oral pharmaceutical dosage form
IL117728A0 (en) Pharmaceutical compositions for transdermal administration
HUP0101437A3 (en) Oral pharmaceutical extended release dosage form
HUP9901037A3 (en) Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
FI955310L (fi) Farmaseuttinen koostumus flavonoidien antamiseksi oraalisesti
IL145559A0 (en) Tolperison-containing pharmaceutical preparation for oral administration
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
SG63824A1 (en) Rapamycin formulations for oral administration
HUP9901349A3 (en) Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUP0003341A3 (en) Rapamycin formulations for oral administration
AU3860797A (en) Pharmaceutical formulations for oral administration
PL325509A1 (en) Therapeutic agent for oral administration
HUP0101012A3 (en) Pharmaceutical composition for oral administration
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
GB9418029D0 (en) Pharmaceutical compositions for oral administration
SI0927031T1 (en) Pharmaceutical preparation containing nimesulide for oral administration
HK1008301A (en) New oral pharmaceutical dosage form
AU3570195A (en) Pharmaceutical composition of fantofarone for oral administration